{"id":"NCT04380519","sponsor":"R-Pharm International, LLC","briefTitle":"Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)","officialTitle":"An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-04-23","primaryCompletion":"2020-07-10","completion":"2020-07-24","firstPosted":"2020-05-08","resultsPosted":"2022-01-24","lastUpdate":"2022-01-24"},"enrollment":372,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"RPH-104 80 mg","otherNames":[]},{"type":"DRUG","name":"Olokizumab 64 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"RPH -104 80 mg","type":"EXPERIMENTAL"},{"label":"Olokizumab 64 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study was to evaluate the efficacy and safety of a single dose of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 15 of the study.","primaryOutcome":{"measure":"Proportion of Responders in Each Treatment Group","timeFrame":"Day 15","effectByArm":[{"arm":"RPH -104 80 mg","deltaMin":88,"sd":null},{"arm":"Olokizumab 64 mg","deltaMin":98,"sd":null},{"arm":"Placebo","deltaMin":87,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.434"},{"comp":"OG001 vs OG002","p":"0.073"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":123},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Gamma-glutamyltransferase increased"]}}